B-SOFT CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.28 CNY | -3.60% |
|
+0.23% | -34.66% |
| Apr. 25 | B-SOFT Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 15 | B-SOFT Co.,Ltd. Proposes Final Cash Dividend for the Year 2023 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -34.66% | 915M | - | ||
| +5.45% | 32.61B | C | ||
| +22.28% | 7.98B | C- | ||
| +25.15% | 3.99B | B- | ||
| -17.83% | 3.13B | C- | ||
| -20.28% | 1.38B | B | ||
| -30.40% | 1.2B | - | ||
| +6.64% | 959M | C | ||
| -27.45% | 819M | - | C+ | |
| -18.08% | 700M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 300451 Stock
- Ratings B-SOFT Co.,Ltd.